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Ultrafast affinity extraction was used with microcolumns containing human serum 
albumin (HSA) to measure the free fractions of several sulfonylurea drugs in the 
presence of solution-phase HSA and for the analysis of these drugs at therapeutic levels 
or determining their binding strengths with this protein.  This approach was first used 
with normal HSA and the drugs glibenclamide, glipizide and glimepiride. This work 
used both one- and two-dimensional affinity systems based on HSA microcolumns.  
The first microcolumn was used to extract the free drug fractions in injected 
drug/protein mixtures.  As the retained drug eluted from the first microcolumn, it was 
passed through a second HSA column for further separation and measurement.  Items 
  
that were considered during the optimization of this approach included the column sizes 
and flow rates that were used and the time at which the second column was placed on-
line with the first HSA microcolumn.  Global affinity constants that were obtained 
from the measured free fractions gave good agreement with those predicted from 
previous binding studies.   
 
The second part of this study examined the binding of sulfonylurea drugs with HSA at 
various stages of glycation.  Affinity microcolumns containing immobilized HSA 
were used to extract the free drug fractions of drug/glycated HSA mixtures.  
Conditions that were considered during method optimization again included the column 
sizes and flow rates that were used for ultrafast affinity extraction.  An apparent 
change in the affinity of the given drugs for HSA was seen at moderate to high levels 
of glycation.  The results throughout this work indicated that affinity microcolumns 
and ultrafast affinity extraction could be used as tools for measuring free drug fractions 
and for examining the interactions of sulfonylurea drugs with normal or modified forms 
of HSA.  The same approach could be utilized with other drugs and proteins or 
modified binding agents of clinical or pharmaceutical interest. 
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Chapter 1 
General Introduction 
1.  Affinity chromatography 
Affinity chromatography is a type of liquid chromatography in which a 
biologically-related agent is used as the stationary phase.1-5  This method is commonly 
used to selectively purify or quantify biologically-related compounds.  The 
biologically-related agent that is immobilized in the column is referred to as the 
“affinity ligand.”  Examples of affinity ligands include enzymes, proteins, DNA or 
RNA, and antibodies or antigens,1-5 which were immobilized onto a solid support in the 
column and are used to bind a complementary molecule in an applied sample.3,6  
Because these interactions are often quite strong and selective, there are usually few 
interferences from other components in the sample.  This unique feature has made 
affinity chromatography an important tool in bioanalytical and clinical analysis.4,7,8 
Based on mechanical stability and size of the support material, affinity 
chromatography can be categorized as being low-performance or high-performance 
affinity chromatography (HPAC).  A disadvantage of low-performance affinity 
chromatography is that it is based on non-rigid and low efficiency supports that make 
it difficult to use at high flow rates and on systems designed for high-performance liquid 
chromatography (HPLC).  However, this disadvantage can be overcome by using 
HPAC and more rigid supports designed for use in HPLC.3,9-12  In this thesis, HPAC 
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was used to study interactions between sulfonylurea drugs and the protein human serum 
albumin (HSA). 
 
2.  Human serum albumin  
HSA is the most abundant protein in human plasma or serum. A lot of free 
fraction and binding studies had been done on HSA with various of drugs, hormones or 
fat acids.  HSA is normally present in serum at concentrations ranging from 496-782 
μM and accounts for approximately 60% of the total protein content in serum.  HSA 
has a molecular weight of 66.7 kDa and is composed of a single polypeptide chain that 
contains 585 amino acids and 17 disulfide chains.13  Crystal structure of HSA shows 
a globular heart-shape for this protein, which is composed of approximately 67% α-
helices, 23% extended chains, and 10% β-turns.14,15   
HSA plays a significant role in many biological processes.  For instance, HSA 
aids in regulating lipid metabolism and transports a wide range of solutes that include 
fatty acids, hormones and drugs.15 There are various binding sites for these solutes on 
HSA.  Among these binding sites, there are two main binding sites for drugs, which 
are often referred to as Sudlow sites I and II.  Sudlow site I tend to bind to bulky 
heterocyclic compounds, such as warfarin, azapropazone, and phenylbutazone.  
Sudlow sites II primarily bind to aromatic compounds such as ibuprofen.  The affinity 
constants for drugs with HSA often range from 103 to 107 M-1 and generally involve the 
formation of a reversible drug-protein complex.3,16-19  The reversible process leads to 
part of a drug existing in both a protein-bound form and an unbound, or free, form in 
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blood.20,21 
The N-terminus and 59 lysine residues on HSA can act as potential sites for the 
formation of early stage glycation products on this protein, as is illustrated by the 
reaction in Figure 1-1.  Glycation is a non-enzymatic process, in which an amine 
group can undergo the formation of a reversible Schiff base with the open chain form 
of a reducing sugar (e.g., glucose).22,23 These changes are efficient and stable enough 
to make the glycation of human serum albumin an alternative marker to glycated 
hemoglobin (or HbA1C) as a marker for glucose control in diabetes.22 
      HPAC has been examined as a technique for studying the binding by drugs with 
proteins such as HSA through methods such as zonal elution and frontal analysis.3,11,15-
17,19-21  The HSA can be immobilized into a normal or affinity microcolumn as a 
stationary phase for use in this work, which is often conduced with a mobile phase such 
as pH 7.4, 0.067 M potassium phosphate buffer to mimic physiological conditions.6,7,13  
HSA can be immobilized through techniques such as the Schiff base method, which 
uses diol-bonded silica as the staring material.3,11,13,15-19  This process involves taking 
the diol-bonded silica and oxidizing the diol groups with periodic acid to give aldehyde 
groups, which can then react with primary amine groups on a ligand such as HSA to 
form a Schiff base.2,24  The drugs of interest can then be applied to this column to 
measure their retention, or they can be injected in the presence or absence of soluble 
HSA (i.e., as will be used in this thesis).3,6,7  In second case, the free or unbound form 
of the drug can be extracted by a small HSA column and then measured as they elute 
4 
 
by using a process known as ultrafast affinity extraction.6,7,16   
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Figure 1-1.  General process of glycation.16,17,23 
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The work in this thesis will use HPAC and ultrafast affinity extraction to measure free 
drug fractions in samples and to use this information to estimate the binding constants 
for drug-HSA interactions. 
 
3.  Free fraction methodology  
Reversible drug-protein interactions in blood result in the formation of a drug-
protein complex and a resulting free, or unbound, fraction for a drug, with the free 
fraction often being believed to represent the biologically-active form.2-4,6 Thus, there 
has been ongoing interest in the development of tools to measure free drug fractions 
and to study drug-protein interactions in clinical samples.7,25-28  Two methods that are 
often used for this purpose are dialysis and ultrafiltration.  However, these methods 
have long analysis times and large sample requirements.29,30 
This work will examine use of HPAC and small columns containing 
immobilized HSA as an alternative approach for these measurements.  This will be 
used with the method of ultrafast affinity extraction, in which these small columns will 
be employed to extract only the free form of a drug on a time scale that minimizes or 
eliminates the release of the drug from its soluble protein-drug complex.3,11,15-17,19-21  
A number of prior reports have used this method to measure the free fractions of various 
drugs and hormones.3,6,7,16 The will involve the use of both single-column and two-
column systems in ultrafast affinity extraction, with the two-dimensional system being 
used to measure the free fractions of the drugs at samples that contain these agents at 
therapeutic levels. Furthermore, analysis of binding constant between sulfonylurea 
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drugs and normal HSA or glycated HSA will be also discussed followed by free 
fractions study. 
 
4.  Sulfonylurea drugs 
      Sulfonylurea drugs are used to treat type 2 diabetes by simulating insulin 
release from pancreatic β cells.30 First-generation sulfonylurea drugs have been used 
for more than 40 years and include chlorpropamide and tolbutamide.  However, these 
drugs have several known side-effects, such as leading to abnormal liver function due 
to drug-drug interactions and drug-alcohol interactions.31 Second-generation 
sulfonylurea drugs are more common today and more cost-effective.  Drugs in this 
group are glipizide, glibenclamide and glimepiride, which are all known to have 
binding with HSA.3,5,32,33 
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Chapter 2 
Free Fraction Analysis of Drug-Protein Binding by Ultrafast Affinity Extraction: 
Interactions of Sulfonylurea Drugs with Human Serum Albumin 
 
1. Introduction 
There were about 366 million people in the world who had diabetes in 2011.1  
Among of those patients, type 2 diabetes makes up approximately 90% of all cases.2  
Type 2 diabetes occurs when the body does not produce enough insulin for proper 
glucose control.3,4  This disease can be treated by stimulating the secretion of insulin 
from β cells in the pancreas, such as by using sulfonylurea drugs (see Figure 2-1).5  
Sulfonylureas drugs are usually categorized as being first-generation or second-
generation, and vary in terms of their dosages and effectiveness in treating type 2 
diabetes.6  For example, the second-generation sulfonylurea drugs glipizide, 
glibenclamide and glimepiride have therapeutic ranges in serum of only 0.24-3.36 uM 
0.08-0.4 μM and 0.18-1.0 μM,7,8 while the first-generation drug tolbutamide has a 
therapeutic range of 185-379 uM.8 
Sulfonylurea drugs are known to bind the transport protein human serum 
albumin (HSA), which is also the most abundant protein in blood.9  Figure 2-2 shows 
binding process occur between HSA and drugs in HPAC study.  The binding results in 
these drugs being present in both a free form and a protein-bound form in blood.10  
Free fraction is generally believed to represent the biologically-active form and is 
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affected by the degree of drug-protein binding that occurs in blood.11  If free fraction 
is not adequately controlled, the result will be either an ineffective dosage for the drug 
(due to a small free fraction) or a drug level that may result in side-effects or toxicity 
(at high free fractions).8 
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Glipizide  
 
 
Glimepiride  
 
 
Glibenclamide  
 
Figure 2-1.  Structures of second-generation sulfonylurea drugs.  The portion in the 
dashed box shows the core structure of these drugs. 
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Figure 2-2.  General process for the separation of a free drug from a protein and drug-
protein complex, as well as measurement of the free drug fraction, by using ultrafast 
extraction and two-dimensional affinity system.  This specific example is for a drug 
that binds to soluble HSA and that uses HSA microcolumns to isolate and measure the 
captured free drug fraction. 
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Ultrafast affinity extraction based on small high-performance columns has 
recently been shown to be a convenient technique to measure the free fractions of drugs 
and to study drug-protein binding in solution.9,11–13  Ultrafast affinity extraction and 
microcolumns containing immobilized HSA will be used in this chapter to measure the 
free fractions for several second-generation sulfonylurea drugs with normal HSA.  
One- and two-dimensional affinity systems will be developed to make free fraction 
measurements for these drugs at typical therapeutic levels and in the presence of 
physiological levels of HSA.  The measured free fractions will also be used to 
determine the binding constants for these drugs with solution-phase HSA.  The 
methods will form a basis for later studies aimed at examining the free fractions for 
these drugs in clinical samples. 
 
2.  Experimental 
2.1.  Reagents  
The glipizide, glibenclamide, glimepiride, and HSA (Cohn fraction V, 
essentially fatty acid free, ≥ 96% pure) were from Sigma (St. Louis, MO, USA).  
Nucleosil Si-300 silica (7 μm particle diameter, 300 Å pore size) was acquired from 
Macherey Nagel (Dűren, Germany).  The components for the bicinchoninic acid 
(BCA) protein assay were purchased from Pierce (Rockford, IL, USA).  All aqueous 
solutions and buffers were prepared using water that was generated by a NANOpure 
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system (Barnstead, Dubuque, IA, USA) and were passed through Osmonics 0.22 μM 
nylon filters from Fisher Scientific (Pittsburgh, PA, USA). 
2.2.  Apparatus 
The microcolumns were packed by utilizing a Prep 24 pump from ChromTech 
(Apple Valley, MN, USA).  The HPLC system consisted of an AS-2057 autosampler, 
a PU-2080 Plus pump, and a UV-2075 absorbance detector from Jasco (Easton, MD, 
USA), which also included a six-port Lab Pro valve (Rheodyne, Cotati, CA, USA).  A 
Jasco X-LC 3167CO column oven was used to maintain a temperature of 37.0 (± 
0.1) °C for the columns during all the chromatographic experiments.  The HPLC 
system was controlled by using ChromNAV v1.18.04 and LCNet software from Jasco.  
The chromatographic data were analyzed by using PeakFit v4.12 software (Jandel 
Scientific, San Rafael, CA, USA). 
2.3.  Microcolumn preparation  
The microcolumns used in this study were prepared by using Nucleosil Si-300 
silica as the starting material.  This support was converted into a diol-bonded form and 
then used in the Schiff base method for the immobilization of HSA, as described 
previously.14  A control support was made in the same manner but with no protein 
being added during the immobilization step.  The protein content of these supports 
was measured by using a BCA protein assay,13 using the control support as the blank 
and soluble HSA as the standard.10,13,15–18  The final support used in this study had a 
measured protein content of 53.6 (± 2.2) mg HSA/g silica.   
17 
 
The column sizes that were used in this work had lengths of 1 mm, 5 mm or 10 
mm and an inner diameter of 2.1 mm.  These columns were packed into stainless steel 
housings by using pH 7.4, 0.067 M potassium phosphate buffer as the packing 
solution.10,19  During the packing process, the packing pressure was increased by 200 
psi every 30 s to a final pressure of 4000 psi, maintained at 4000 psi for 40 min, and 
then decreased by 200 psi every 30 s to about 100 psi.  After done packing, the 
columns washed by applying pH 7.4, 0.067 M potassium phosphate buffer at 0.5 
mL/min for at least 30 min, then stored in the pH 7.4 buffer at 4°C until use.  Retention 
of the columns was initially tested by injecting both sodium nitrite (a non-retained 
solute on this type of column) and R-warfarin (a drug which is strongly retained by 
HSA); The injections gave a retention factor for R-warfarin of 15.6 (± 0.3) at 0.5 
mL/min and 14.7 (± 0.4) at 1.0 mL/min in the presence of pH 7.4, 0.067 M phosphate 
buffer and at 37ºC. 
 
 
2.3.2.  Chromatographic studies 
A single-column affinity system was first used to find the optimum flow rate for 
sample injection during ultrafast affinity extraction.  In later work, a two-column 
system was used in which the first column was connected to a second column by using 
a six-port valve.  In both systems, a short HSA microcolumn was used to extract a free 
drug fraction from a sample.  In the two-column system, a longer second HSA column 
was placed on-line with the first to further isolate the extracted free fraction from other 
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sample components.20   
Single-column system was initially evaluated by using samples that contained 
similar concentrations of HSA and each drug of interest.  Samples contained 10 or 20 
μM HSA and 10 μM of a drug in the pH 7.4, 0.067 M phosphate buffer that was also 
being used as the mobile phase.  All drug/HSA mixtures that were used in this study 
were mixed and incubated at 37℃ for at least 30 min prior to injection and to reach 
equilibrium between a drug and its drug-protein complex in the sample.  In later 
studies with the two-column system, samples that contained the following typical 
therapeutic concentrations of the drugs were prepared: glibenclamide, 0.08 μM; 
glipizide, 2.24 μM; and glimepiride, 0.4 μM.7,8,21  Concentration of HSA was 500 or 
600 μM in these samples, as chosen to represent a typical physiological level for this 
protein (496-782 uM).22  A 5 μL sample volume was used for injection throughout this 
report, and all injections were made four times.   
     HSA microcolumns that were used in the single-column systems or as the first 
column in the two-dimensional systems had the following dimensions: 5 mm × 2.1 mm 
i.d. for glipizide and glimepiride; and 1 mm × 2.1 mm i.d. for glibenclamide.  Size of 
second HSA column in the two-dimensional system was 10 mm × 2.1 mm i.d. for 
glipizide and glimepiride, and 5 mm × 2.1 mm i.d. for glibenclamide.  Final flow rates 
that were used for injection and sample elution were 3.5 mL/min for glipizide, 3.0 
mL/min for glimepiride, and 0.3 mL/min for glibenclamide.  Wavelengths used for 
absorbance detection were as follows: 242 nm for glibenclamide, 275 nm for glipizide, 
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and 245 nm for glimepiride.23–25 
 
3.  Results and discussion 
3.1.  Optimization of conditions for ultrafast affinity extraction 
Before ultrafast affinity extraction can be used to measure free drug fractions, 
there are several conditions that need to be considered.  First, residence time for the 
sample in the affinity microcolumn needs to be sufficiently small to avoid significant 
dissociation of the protein-bound drug fraction in the sample.  The factor can be varied 
by adjusting the column size and flow rate.  A related factor to consider is that a long 
column will provide higher retention and a better separation of the eluted protein-bound 
and free drug fractions.  For example, a drug such as glibenclamide which has strong 
binding to HSA (equilibrium constant, 2.1 × 106 M-1) and will give good retention even 
on a 1 mm long column, while a 5 mm long column might be needed for a drug such 
as glipizide with slightly lower binding (4.4 × 105 M-1).24,25  In addition, back pressure 
will vary with column size.  For example, a shorter column will have a lower back 
pressure and can be used at higher flow rates.  After several trails regarding the 
selection of size for the HSA microcolumns that were to be used in this study, it was 
determined that column sizes of 1-10 mm × 2.1 mm i.d. should work well in this project.  
The columns could be used at a flow rate of up to 4 mL/min, giving back pressures up 
to 4 MPa under these operating conditions. 
 Experiments were first conducted to find the optimum flow rates that could be 
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used both in a single-column system and later in a two-column for ultrafast affinity 
extraction of sulfonylurea drugs to measure their free fractions in presence of HSA at 
therapeutic drug levels.  This study was carried out by injecting samples over a range 
of flow rates and using the following column sizes: 5 mm × 2.1 mm i.d. for glipizide 
and glimepiride, and 1 mm × 2.1 mm i.d. for glibenclamide.  Apparent free fraction 
decreased as flow rate was increased and reached a plateau as free fraction reached the 
value that was present in original sample.  This effect was due to dissociation of drugs 
from drug-protein complexes that were present in the sample when using low-to-
moderate flow rates; however, it has been shown the effect can be eliminated or 
minimized by raising flow rate at or above a given threshold level.  
Experiments were conducted to identify the flow rate conditions needed to reach  
threshold region in free fraction measurements for given sulfonylurea drugs in the 
presence of soluble HSA.  These early studies were carried out by injecting 5 μL 
samples that contained 5-10 μM of the desired drug or a mixture containing 5-10 μM 
of this drug and 10-20 μM of normal HSA.  The results are summarized in Table 2-1 
and in Figure 2-3.  It was found that glipizide gave a consistent free fraction at an 
injection flow rate of 3.5 mL/min or greater when using a 5 mm × 2.1 mm i.d. HSA 
microcolumn.  Glibenclamide gave a consistent free fraction at an injection flow rate 
of 0.3 mL/min or greater when using a 1 mm × 2.1 mm i.d. HSA microcolumn, and 
glimepiride gave a consistent free fraction at a flow rate of 3.0 mL/min or greater when 
using a 5 mm × 2.1 mm i.d. HSA microcolumn.  Column back pressure ranged from 
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1.9-4.0 MPa under the conditions. Principle to starting flow rate pick-up is relative low, 
since multiple factor need to be considered. First, resolution: Starting with high flow 
will cause retained peak to appear sooner, and it may cause non-retained and retained 
peak overlapped. Second, back pressure: high flow rate will increase back pressure of 
system. Third, economy: high flow rate used more buffer.  Resulting maximum 
column residence times that were created under these same conditions were as follows: 
glipizide, 238 ms; glibenclamide, 277 ms; and glimepiride, 554 ms.  The range of 
residence times was similar to what has been noted in the use of ultrafast affinity 
extraction to examine binding of HSA with other sulfonylurea drugs (e.g., values of 
333-665 ms for acetohexamide and gliclazide).10,13   
Figure 2-4 shows examples of chromatogram that were obtained from glipizide 
in these studies.  In the chromatogram, the non-retained peak for soluble protein and 
drug-protein complex appeared at 20-30s.  Retained peak for the captured free drug 
appeared at 50-60 s.  Similar chromatograms were observed for glibenclamide and 
glimepiride, with the main difference being the time at which the non-retained and 
retained peaks appeared. 
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Figure 2-3(a) 
 
 
 
Figure 2-3(b) 
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Figure 2-3(c) 
Figure 2-3.  Determination of optimum flow rates for the measurement of free 
fractions in samples containing (a) 10 µM glipizide + 20 µM HSA, (b) 10 µM 
glibenclamide + 10 µM HSA and (c) 10 µM glimepiride + 10 µM HSA, which were 
injected into 5 mm × 2.1 mm, 1 mm × 2.1 mm or 5 mm × 2.1 mm i.d. HSA affinity 
microcolumns, respectively.  The error bars represent ± 1 S.D. 
 
 
 
 
 
 
 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 0.5 1 1.5 2 2.5 3 3.5 4
Fr
ee
 F
ra
ct
io
n
Flow Rate(mL/min)
24 
 
 
Figure 2-4.  Typical chromatograms obtained at pH 7.4 and 37ºC on a 5 mm × 2.1 
mm i.d. HSA microcolumn at 3 mL/min for 5 µL injections of 10 µM glipizide in the 
absence or presence of 20 µM HSA. 
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Table 2-1. Optimum flow rates obtained for free fraction measurements using a 
single-column affinity system for sulfonylurea drugs in the presence of soluble HSA 
Drug and sample Optimum flow rate 
(mL/min) 
Apparent free 
fractiona 
Glipizide (10 μM)  
    + HSA (20 μM) 
3.5 13.9 (±1.2)% 
Glibenclamide (10 μM)  
    + HSA (10 μM) 
          0.3 19.6 (±1.5)% 
Glimepiride (10 μM) 
    + HSA (10 μM) 
          3.0 28.1 (±2.9)% 
 
aThe values in parentheses represent a range of ± 1 S.D. 
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3.2.  Detection of free drug fractions at therapeutic levels on a single-column system 
Some second-generation sulfonylurea drugs have relatively low therapeutic 
levels and low free fractions.  Specific examples are glibenclamide, with a therapeutic 
range of 0.08-0.40 μM, and glimepiride, with a therapeutic range of 0.18-1.02 μM.7,8  
In these cases, a low limit of detection would be needed to measure free fraction.  Thus, 
parameter was examined on a single-column system during early stages of this work.28  
Item was evaluated by injecting various concentrations for each drug of interest.  
Range of concentrations used for these drugs included a blank (0.0 μM) and following 
concentrations: glibenclamide, 0.05-0.45 μM; and glimepiride, 0.1-5.0 μM.  The 
limits of detection that were obtained for glibenclamide and glimepiride were 0.039 μM 
and 0.027 μM, which were determined to not be acceptable for later the measuring free 
concentrations of these drugs at therapeutic levels. 
 
3.3.   Use of a two-dimensional affinity system to measure free fractions at 
therapeutic levels 
Next section looked at the use of a two-dimensional affinity system to look at 
therapeutic free fractions of second-generation sulfonylurea drugs7,8 (glipizide: and in 
the presence of physiological levels of HSA (i.e., 496-782 μM).17  Under the 
conditions, single-column system did not give baseline resolution between extremely 
small retained peak for free drug fraction and the large non-retained peak for HSA and  
drug-HSA complex.  A second HSA microcolumn that was coupled with the first 
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through a switching valve to overcome this problem, as shown in Figure 2-2. 
Figure 2-5 shows effect on the apparent free drug fractions when using 
various times for switching second column on-line with first HSA microcolumn.  
Apparent free fractions reached a minimum and a plateau value for glipizide at 1.3 min 
and when using a flow rate of 1.5 mL/min with a second HSA column that had a size 
of 1.0 cm × 2.1 mm i.d.  For glibenclamide, condition was reached when using a valve 
switching time of 4.9 min at flow rate of 0.15 mL/min and a second HSA column with 
a size of 5 mm × 2.1 mm i.d.  Results for glimepiride gave a consistent free fraction 
at a switching time of 1.4 min and at a flow rate of 1.0 mL/min with a second HSA 
column that had a size of 1 cm × 2.1 mm i.d.   
Table 2-2 shows relationship between measured free fractions and valve 
switching times.  Initial decrease in the apparent free fraction as valve switching time 
was increased was due to more effective isolation of free drug fraction from drug-
protein complex and non-retained HSA from first column.  As the contaminates were 
minimized at longer switching times, only the “true” free drug fraction was passed 
through second HSA column, which now gave a consistent value for fraction. 
 
 
 
 
28 
 
 
Figure 2-5(a) 
 
Figure 2-5(b) 
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Figure 2-5(c) 
 
Figure 2-5.  Valve switch time finding on measurement of free fraction by a two-
dimensional system for a sample that contained (a) 2.24 µM glipizide + 600 µM HSA, 
(b) 0.08 µM glibenclamide and (c) 0.40 µM glimepiride + 500 µM HSA.  These 
measurements were made at pH 7.4 and 37 ℃.  The error bars represent ± 1 S.D. 
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Table 2-2. Effect of valve switching time on the apparent free fractions measured for 
sulfonylurea drugs in a two-column affinity system 
Drug and sample Measured 
free fraction 
Valve switching 
time (min) 
Glipizide (2.24 μM)  
    + HSA (600 μM) 
0.37 (± 0.12)% 1.3 
Glibenclamide (0.08 μM)  
    + HSA (500 μM) 
 0.10 (± 0.03)% 4.9 
Glimepiride (0.4 μM)  
    + HSA (500 μM) 
 0.22 (± 0.11)% 1.5 
aThese free drug fraction values were determined at pH 7.4 and 37ºC by using ultrafast 
affinity extraction. The values in parentheses represent a range of ± 1 S.D. (n = 4), as 
determined by error propagation 
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3.4 Estimation of binding constants from measured free fractions 
Free fraction results that were obtained by using ultrafast affinity extraction and 
two-dimensional affinity system were used to calculate association equilibrium 
constants or global affinity (Ka) for each of sulfonylurea drugs with HSA.  It is known 
that sulfonylurea drugs bind with both Sudlow sites I and II of HSA, the major drug 
binding regions of this protein.8,9,30–33,10,13,15–18,26,29  Global affinity constant was 
calculated by using Eq. 2-1 and measured free fraction for drugs, along with the known 
total concentration of HSA and the drug in the sample.10,11,13,15,17,18,26,29,34 
𝐾a =
1−𝐹
𝐹([P]−[D]+[D]𝐹)
                             (2-1)  
In the equation, F is measured free fraction, [P] is the total concentration of soluble 
protein (HSA), and [D] is total concentration of the drug.   
Tables 2-3 and 2-4 show values of Ka that were obtained by using Eq. 2-1 with one 
column and two-dimensional systems, respectively, along with values that have been 
reported for same interactions in the literature.13,18,26,29  In general, there was no 
significant difference at the 95% confidence level between these experimental results 
and literature values for the drugs that were examined at therapeutic concentrations. 
Overall affinity constants for the second-generation sulfonylurea drugs with HSA were 
one order of magnitude higher than first generation sulfonylurea drugs.  For instance, 
glipizide, glibenclamide and glimepiride had affinity constants of 4.5 × 105 M-1, 2.0 
× 106 M-1, and 9.3 × 105 M-1, compared with values for tolbutamide, acetohexamide 
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and chlorpromazine of 1.1 × 105 M-1, 1.8 × 105 M-1, 6.2 × 105 M-1.26 
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Table 2-3. Estimated binding constants obtained by using a one-column affinity system 
Drug and sample Affinity constant, Ka (× 105 M-1) 
Glipizide (10 μM)  
    + HSA (20 μM) 
5.4 (±0.6) 
Glibenclamide (10 μM)  
    + HSA (10 μM) 
          20.8 (±3.4) 
Glimepiride (10 μM)  
    + HSA (10 μM) 
          9.1 (±2.2) 
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Table 2-4. Comparison of measured overall affinity constants with literature values, 
based on results obtained with a two-dimensional affinity system 
Sample and drugs Overall affinity constant, 
Ka (× 105 M-1) 
  This study Literature13,18,26,29 
Glipizide (2.24 μM)  
    + HSA (600 μM) 
4.5 (± 1.5) 4.4 (± 1.2) 
Glibenclamide (0.08 μM) 
     + HSA (500 μM) 
20.0 (± 6.0) 21.0 (± 8.0) 
Glimepiride (0.4 μM)  
    + HSA (500 μM) 
9.1 (± 3.3) 9.3 (± 3.8) 
aThese global affinity constants are based on the free drug fractions listed in Table 2-2 
and were calculated by using Eq. 2-1.  The values in parentheses represent a range of 
± 1 S.D. (n = 4), as determined by error propagation. 
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3.5   Determination of dissociation rate constants by ultrafast affinity extraction 
      The data that were generated during the measurement of free drug fractions by  
single-column system were alo used to estimate dissociation rate constants for  
sulfonylurea drugs from HSA.  This was done by using the data that were obtained at 
low-to-moderate flow rates during ultrafast affinity extraction, as described previously 
for other solute/protein systems.26  Dissociation rate constant was obtained from the 
datas by using either Eqs. 2-2 or 2-3. 
                             𝑙𝑛
1−𝐹
1−𝐹𝑡
 = kd t                                                 
(2-2)  
                             𝑙𝑛
1
(1−𝐹𝑡)
 =kd t - ln(1 - F)                                        
(2-3) 
In equations, F is measured free fraction of drugs in the original sample (e.g., as 
measured at short column residence times), and Ft is apparent free fraction that is 
measured when drug-protein complex has been allowed to dissociate in column for time 
t.  The value of t is equal to the sample residence time, which depends on column void 
volume and flow rate that was used for sample injection.   
Some typical plots that were obtained when using Eqs. 2-2 and 2-3 are provided 
in Figure 2-6.  Both types of plots gave an approximately linear response for all of 
tested drugs, with correlation coefficients ranging from 0.981 to 0.987 (n = 5 to 6) over 
dissociation times that allowed measurable changes to be made in the apparent free 
fractions. Plots that were prepared according Eq. 2-2 gave intercepts that were equal to 
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zero, regardless of whether an experimental point at t = 0 and Ft = F0 for original sample 
was included in the data set.  For plots made according to Eq 2-3, a positive nonzero 
intercept was obtained that was related to the value of F0.  In both cases, the value of 
kd could be obtained from slope of plot.  
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Figure 2-6(a) 
 
Figure 2-6(b) 
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Figure 2-6(c) 
 
 
Figure 2-6(d) 
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Figure 2-6(e) 
 
 
Figure 2-6(f) 
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Figure 2-6. Determination of the dissociation rate constants for glipizide, 
glibenclamide and glimepiride with soluble HSA at pH 7.4 and 37℃ by using single-
column ultrafast extraction. The plots in (a-b) are for glipizide using Eqs. 2-2 and 2-3, 
respectively, (c-d) are for glibenclamide and (e-f) are for glimepiride. Correlation 
coefficients (r) for these plots were 0.981-0.987 (n = 4 to 6).  The error bars represent 
± 1 S.D. 
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Both types of plots gave a linear response for all three sulfonylurea drugs, 
as is illustrated in Figure 2-6.  Table 2-5 shows the kd values that were obtained from 
these plots.  In general, range of the dissociation rate constants that were measured in 
this study gave good agreement with values that have been reported for similar drugs 
(same class drugs and same binding site) with HSA.26 For instance, the first-generation 
sulfonylurea drugs tolbutamide, acetohexamide and chlorpromazine have been found 
to have kd values of 0.58-0.59, 0.63-0.67, and 3.55-3.96 s-1 with HSA, respectively.26 
The ranges fit with values that were seen in this chapter for glipizide, glibenclamide 
and glimepiride, which were 1.45-1.57, 0.63-0.75, and 1.03-1.04 s-1.  
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Table 2-5.  Dissociation rate constants estimated for sulfonylurea drugs with HSA 
 Dissociation rate constant, kd (s-1) 
 
Drug 
 
Estimate (Eq. 2-2) Estimate (Eq. 2-3) 
Glipizide 
 
0.69 (± 0.12) 0.65 (± 0.14) 
Glibenclamide 
 
0.40 (± 0.08) 0.44 (± 0.03) 
Glimepiride 0.54 (± 0.09) 0.78 (± 0.12) 
 
aThe kd values were measured at pH 7.4 and at 37 °C. The values in the parentheses 
represent a range of ± 1 S.D., as determined from the slopes of the best-fit lines 
constructed according to Eqs. 2-2 and 2-3.  
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4.  Conclusions 
In this study, ultrafast affinity extraction coupled with a two-dimensional 
affinity system were used to measure free drug fractions at therapeutic levels.  Free 
drug fractions were also used to determine the binding constants for three second-
generation sulfonylurea drugs in presence of HSA.  There were two steps to acquiring 
these measurements.  First step was to find the optimum flow rates, column sizes, and 
residence times for isolation of free drug fractions. Optimum flow rate pick-up at “flat” 
range based on several considerations. Lower back pressure, good peak retention and 
resolution, also having good agreement with previous binding study18,29,35 are key factor 
for final selection of optimum flow rate. Second step was to determine the optimum 
time to place the second column on-line with the first for the accurate measurement of 
tfree fractions at therapeutic levels and in the presence of physiological levels of HSA. 
     There are several advantages for this method. First, use of ultrafast affinity 
extraction and HSA microcolumns can provide relatively fast extractions and strong 
binding to sulfonylurea drugs, which can be used to eliminate or minimize dissociation 
of these drugs from their drug-protein complexes in sample. Second, this system could 
be used under conditions that mimicked physiological conditions and looked directly 
at drug-protein interactions in solution. Third, results of affinity constants were 
consistent with literature values. Finally, volume of sample that was required in this 
method could be as low as to 5 μL and gave detection limits as low as to 0.03 μM for 
glibenclamide and 0.27 μM for glimepiride. Same approach could be applied to other 
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drug–protein systems. Future applications could include use of this method for clinical 
analysis of free drug levels or tudy of additional drug-protein interactions.10,15,17,26,29,36 
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Chapter 3 
Studies of Interactions by Glycated Human Serum Albumin with Sulfonylurea 
Drugs by High-Performance Affinity Chromatography 
 
Introduction 
Diabetes mellitus is a metabolic disease in which a person has high blood sugar 
levels.  The situation can arise either because pancreas does not produce enough 
insulin or because cells do not respond to insulin that is produced.1,2  There are three 
types of diabetes: type 1, type 2 and gestational diabetes.3  Among those patients who 
have been diagnosed with diabetes, more than 90% have type 2 diabetes, which is 
characterized by resistance to insulin or impairment of insulin secretion.42  The 
International Diabetes Federation reported in 2015 that 415 million people in the world 
have diabetes.  A total of 44.3 million are affected by diabetes in North America 
alone.56  
Sulfonylurea drugs are commonly used to treat type 2 diabetes.  The drugs 
target pancreatic beta cells to produce more insulin, which decreases blood glucose 
levels.7,8,9 There are two general types of sulfonylurea drugs.  First-generation 
sulfonylurea drugs were marketed more than 40 years ago and are rarely prescribed 
today. Most common first-generation sulfonylureas are chlorpropamide and 
tolbutamide.2 However, first-generation sulfonylureas drugs tend to suffer from more 
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side-effects than newer drugs and require higher dosages.  For example, the newer 
sulfonylurea drug glipizide has a therapeutic concentration in serum of 0.22-2.24 µM, 
compared with 185-370 µM for tolbutamide.10   
First-generation drugs have now been mainly replaced by second-generation 
sulfonylureas drugs, which are better tolerated, more cost-effective, and have adverse 
effects that are only mild and/or reversible.2  Figure 3-1 shows some examples of these 
newer drugs (e.g., glipizide, glibenclamide and glimepiride) and shows core structure 
of a sulfonylurea drug, which is composed of phenylsulfonyl and urea groups.11  This 
core structure contributes to both the effectiveness and metabolism of the drugs. 
Human serum albumin (HSA) is most abundant protein in human serum.  HSA 
serves as a transport protein for a wide range of solutes, that include many drugs and 
low mass hormones.12 There are several binding sites located in the structure of this 
protein and two major binding sites for drugs (i.e., Sudlow sites 1 and 2), in addition to 
several minor binding sites for drugs.13–17    
Glycation is a non-enzymatic process in which an amine group on a protein 
undergoes a reversible reaction with glucose to form a Schiff base.15,16,18–21 Level of 
glycation that occurs is dependent on the concentration of glucose that is present during 
this reaction.12,21,22  Prior work has indicated that even healthy people have 6-13% of 
their HSA that is glycated, with the amount increasing up to 20-30% in diabetic 
patients.12  A number of previous studies have shown that glycation can alter the 
interactions between HSA and some drugs.16,17,21,23–27 
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The goal of this study is to measure the levels of binding and resulting free (non-
bound) fractions for several second-generation sulfonylurea drugs with HSA that has 
undergone various stages of glycation. Measurements will be made by using the 
technique of ultrafast affinity extraction on a single-column system (see Figure 3-1).  
In this method, HSA will be mixed with each drug and allowed to form a reversible 
drug-protein complex.  Samples will then be injected onto an HSA microcolumn 
under short column residence times to extract the remaining free (non-bound) form of 
the drug in sample and to measure free fraction.24,37  The global affinity constants for 
these interactions will be determined from the measured free fractions and compared 
with the values determined earlier for normal HSA to see how glycation has influenced 
the binding processes. 
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Figure 3-1. General process for the separation between a free drug and protein and 
measurement of free drug fraction by using ultrafast extraction. 
 
 
 
 
 
 
 
 
 
 
 
 
2.   Experimental 
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2.1.  Reagents 
The HSA (Cohn fraction V, essentially fatty acid free, ≥ 96% pure), glipizide, 
glibenclamide and glimepiride were from Sigma (St. Louis, MO, USA).  The reagents 
for the bicinchoninic acid (BCA) protein assay were obtained from Pierce (Rockford, 
IL, USA).  The Nucleosil Si-300 silica (7 μm particle diameter, 300 Å pore size) was 
from Macherey Nagel (Dűren, Germany).  All buffers and aqueous solutions were 
prepared using water from a NANOpure system (Barnstead, Dubuque, IA, USA) and 
were passed through Osmonics 0.22 μm nylon filters from Fisher Scientific (Pittsburgh, 
PA, USA). 
 
2.2.  Apparatus 
The microcolumns were packed using a Prep 24 pump from ChromTech (Apple 
Valley, MN, USA).  The HPLC system consisted of a PU-2080 Plus pump, an AS-
2057 autosampler, and a UV-2075 absorbance detector from Jasco (Easton, MD, USA), 
with the addition of a six-port Lab Pro valve (Rheodyne, Cotati, CA, USA).  A Jasco 
X-LC 3167CO column oven was used to maintain the temperature at 37.0 (± 0.1) °C 
for the columns during all experiments in this report.  ChromNAV v1.18.04 software 
and LCNet from Jasco were used to control the system.  Chromatograms were 
analyzed through the use of PeakFit v4.12 software (Jandel Scientific, San Rafael, CA, 
USA). 
 
3.  Methods 
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3.1  Column and glycated HSA preparation 
Glycated HSA samples were made in vitro, as described in previous work.26-29 
Briefly, HSA was incubated in two separate batches with 15 mM or 30 mM glucose 
under sterile conditions for four weeks at a physiological concentration of HSA and at 
pH 7.4 and 37°C to mimic the conditions that lead to HSA glycation in the circulation.  
After glycation was finished, gHSA was purified according to prior methods26-29 and 
stored at 4°C. Level of glycation was measured by using a glycated serum protein assay 
from Diazyme (San Diego, CA, USA).  This assay gave a measured glycation level of 
1.40 (± 0.06) mol hexose/mol HSA for gHSA1, which was obtained for HSA that was 
incubated with 15 mM glucose.  A glycation level of 3.24 (± 0.07) mol hexose/mol 
HSA was measured for gHSA2, which was obtained for HSA that was incubated with 
30 mM glucose. Glycation levels of gHSA1 and gHSA2 were representative of values 
that would be seen for patients with mild or advanced diabetes, respectively.30,31 
Starting material that was used to make stationary phase was diol-bonded silica, 
which was produced from Nucleosil Si-300 silica according to previous methods.24–26 
The Schiff base method was used to immobilize normal HSA onto the diol-bonded 
silica, also as reported previously.32,33  Same process was used to prepare control 
supports, for which no HSA was added during immobilization step.  A BCA assay 
was carried out in triplicate to determine protein content of each support, using soluble 
and normal HSA as the standard and the control support as the blank.34–36 Final support 
containing immobilized normal HSA was found to have a protein content of 58.7 (± 
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3.5) mg HSA/g silica.   
The HSA and control supports were downward slurry-packed into separate 2.1 
mm I.D. columns with lengths of 1.0 mm or 5.0 mm.  Columns were packed at 4000 
psi using pH 7.4, 0.067 M potassium phosphate buffer as the packing solution.  The 
columns were then washed on an HPLC system with water at 0.1 mL/min for one hour, 
followed by the application of pH 7.4 potassium phosphate buffer at 0.5 mL/min for at 
least half an hour, then stored at 4 ºC in the same pH 7.4 phosphate buffer.  The 
retention of the HSA column was initially tested by injecting both sodium nitrite (a non-
retained solute on this type of column) and R-warfarin (a drug which is strongly retained 
by HSA); Injections gave a retention factor for R-warfarin of 15.6 (± 0.3) at 0.5 mL/min 
and 14.7 (± 0.4) at 1.0 mL/min in the presence of the pH 7.4, 0.067 M phosphate buffer 
and at 37ºC. 
Glipizide, Glibenclamide and Glimepiride all have relatively low solubility in 
an aqueous solution such as a pH 7.4, 0.067 M phosphate buffer. Around 200 μM of 
each drug was typically dissolved in pH 7.4, 0.067 M phosphate buffer within a week 
or at least four days by periodically stirring and sonicating the solution (e.g., every four 
hours, alternatively, during the day, and with only stirring at night) at room temperature. 
UV absorbance of this solution was measured periodically to ensure the drugs were 
dissolved completely.  Once the drug had dissolved, the solutions were passed through 
a 0.2 µm nylon filter three times and stored at 4°C.  The resulting stock solutions were 
further diluted with pH 7.4, 0.067 M phosphate buffer to desired concentration for use 
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in chromatographic studies. Stock solutions were stable for about a week and were kept 
at 25°C for half an hour before use. 
 
3.2  Chromatographic studies 
The ultrafast affinity extraction was performed on a single-column system, as 
illustrated in Figure 3-2.24,37  Based on prior work that was conducted with same drugs 
and using soluble samples of normal HSA, the following column sizes were used for 
these experiments: 5.0 mm × 2.1 mm i.d. for glipizide and glimepiride, and 1.0 mm 
× 2.1 mm i.d. for glibenclamide. Detection of wavelengths were 275 nm for glipizide, 
242 nm for glibenclamide, and 245 nm for glimepiride.38-41 
The mobile phase was pH 7.4, 0.067 M potassium phosphate buffer. Buffer was 
filtered and degassed for 30 min prior to its use on an HPLC system.  All samples 
containing sulfonylurea drugs were dissolved in this buffer.  Besides drugs, some of 
the samples also contained glycated HSA. The drug/protein mixtures were incubated 
for at least 30 min at 37ºC before injection, which was used to allow drug and protein 
to reach an equilibrium between the free drug and drug-protein complexes in the 
samples. Concentration of the drugs in these mixtures was 10 µM, and the concentration 
of any added glycated HSA was 10 or 20 µM.  Replicate 5 µL injections (n = 4) were 
made for both the drug and drug/protein samples.   
 
4.  Results and discussion 
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4.1.  Optimization of conditions for ultrafast extraction 
Column sizes and sample application flow rates were both adjusted to allow the 
use of ultrafast extraction to measure the free fractions for the drugs used, as described 
for normal HSA.24,37,42 HSA microcolumns were used at flow rates up to 4.0 mL/min.  
These conditions gave back pressures up to 4 MPa, which were well within acceptable 
limit for the HPLC system (i.e., which can typically handle up to 25 MPa).  
Glibenclamide has stronger binding to HSA than glipizide and glimepiride;16,24,25 which 
allowed a shorter column to be used for glibenclamide than for other drugs during 
ultrafast affinity extraction.  The HSA microcolumns that were used in these 
experiments had sizes of 5.0 mm × 2.1 mm I.D. for glipizide or glimepiride, and 1.0 
mm × 2.1 mm I.D. for glibenclamide. 
      Injections flow rate was used with these microcolumns to further adjust and 
control sample residence time.24  At low-to-moderate injection flow rates, the 
drug/protein complex would stay in affinity microcolumns for a relatively long time, 
leading to some dissociation of drugs from their protein complexes and giving a higher 
apparent free fraction than was present in original sample.  However, this effect could 
be eliminated or diminished when flow rate was raised up to a certain point that no 
longer allowed sufficient dissociation and thus gave an accurate measurement of the 
drug’s “true” free fraction in sample.24,25     
The effect of flow rate on the measured free fractions is illustrated in Figures 
3-3 and 3-4 for each of the drugs and types of drug/protein mixtures that were examined.  
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For instance, it was found that free fraction for glipizide reached a consistent value at a 
flow rate of 3.0 mL/min or higher when the drug was mixed with gHSA1 and at a flow 
rate of 3.6 ml/min or higher when it was mixed with gHSA2 and applied to a 5.0 mm 
× 2.1 mm I.D. HSA microcolumn.  A flow rate of 3.5 mL/min or higher gave a similar 
condition when using either gHSA1 or gHSA2 with glimepiride on a 5.0 mm × 2.1 mm 
I.D. HSA microcolumn.  A flow rate of 0.4 mL/min or higher gave similar results for 
glibenclamide in the presence of gHSA1 and at a flow rate of 0.35 mL/min or higher 
for gHSA2 and glibenclamide when using a 1.0 mm × 2.1 mm I.D. HSA microcolumn.  
Tables 3-1 and 3-2 show results for measured free fractions and corresponding flow 
rates that were used in measurements.  These flow rates conditions were similar to 
those obtained previously for samples containing normal HSA and gave maximum 
column residence times of 231-277 ms for glipizide in the presence of gHSA1 or 
gHSA2; 415-475 ms for glibenclamide in the presence of modified proteins; and 238 
ms for glimepiride in the presence of either gHSA1 or gHSA2.  
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Figure 3-2(a) 
 
Figure 3-2(b) 
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Figure 3-2(c) 
Figure 3-2.  Apparent free fractions for samples containing (a) µM glipizide + 10 µM 
gHSA1, (b) µM glibenclamide + 10 µM gHSA1 or (c) 10 µM glimepiride + 10 µM 
gHSA1 when injected into 5 mm × 2.1 mm, 1 mm × 2.1 mm or 5 mm × 2.1 mm i.d. 
HSA affinity microcolumns, respectively.  The error bars represent ± 1 S.D. 
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Figure 3-3(a) 
 
Figure 3-3(b) 
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Figure 3-3(c) 
Figure 3-3.  Apparent free fractions measured for samples containing (a) 10 µM 
glipizide + 10 µM gHSA2, (b) 10 µM glibenclamide + 10 µM gHSA2 or (c) 10 µM 
glimepiride + 10 µM gHSA2 when injected into 5 mm × 2.1 mm, 1 mm × 2.1 mm or 5 
mm × 2.1 mm i.d. HSA affinity microcolumns, respectively.  The error bars represent 
± 1 S.D. 
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Table 3-1.  Apparent free fractions measured for sulfonylurea drugs with gHSA1 
using an HSA affinity microcolumna 
 
Drug and sample Measured 
free fraction 
Flow rate 
(mL/min) 
Glipizide (10 μM) 
    + gHSA1 (20 μM) 
17.3 (± 2.7)% 3.00 
Glibenclamide (10 μM) 
    + gHSA1 (10 μM) 
21.4 (± 1.4)% 0.30 
Glimepiride (10 μM) 
    + gHSA1 (10 μM) 
28.1 (± 2.9)% 3.50 
aThese free drug fraction values were determined at pH 7.4 and 37ºC by using 
ultrafast affinity extraction.  The values in parentheses represent a range of ± 1 S.D. 
(n = 4). 
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Table 3-2.  Apparent free fractions measured for sulfonylurea drugs with gHSA2 
using an HSA affinity microcolumna 
 
Drug and sample Measured 
free fraction 
Flow rate  
(mL/min) 
Glipizide (10μM) 
    + gHSA2 (10 μM) 
16.9 (± 3.8)% 3.50 
Glibenclamide (10 μM) 
    + gHSA2 (10 μM) 
22.9 (± 2.8)% 0.35 
Glimepiride (10 μM) 
    + gHSA2 (10 μM) 
35.5 (± 6.2)% 3.50 
aThese free drug fraction values were determined at pH 7.4 and 37ºC by using 
ultrafast affinity extraction.  The values in parentheses represent a range of ± 1 S.D. 
(n = 4). 
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Figure 3-4 shows some typical chromatograms that were obtained, using 
glipizide as an example.  In the example the non-retained peak for the soluble HSA 
and drug-protein complex appeared at 40-50 s when using a flow rate of 3.0 mL/min 
on a 5.0 mm × 2.1 mm I.D. microcolumn. Retained peak for free drug fraction appeared 
at 70-80 s.  Similar chromatograms were observed for glibenclamide and glimepiride, 
will all have retained free fraction peaks eluting within 3 min under final optimized 
conditions. 
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Figure 3-4.  Typical chromatograms obtained at pH 7.4 and 37°C on a 5 mm × 2.1 
mm i.d. HSA microcolumn at 2.25 mL/min for 5 µL injections of 10 µM glipizide in 
the absence or presence of 20 µM gHSA1. 
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3.2.  Estimation of global affinity constants for sulfonylurea drugs with glycated 
HSA 
Results obtained for the free fraction measurements by ultrafast affinity 
extraction in Tables 3-1 and 3-2 were used to estimate the overall affinities of the 
sulfonylureas drugs with glycated HSA.  The drugs are known to have at least two 
major binding sites on HSA (i.e., Sudlow sites I and II, with glipizide also binding to 
the digitoxin site of this protein).16–17,25,37,43 The global affinity constants for 
interactions were calculated from the known content of the drug/protein samples and 
measured free fractions by using Eq. 3-3, which was obtained by combining Eqs.3-1 
and 3-2.25,43-45 
            F=
[𝐃]−[𝐃𝐏]
[𝐃]
                                            (3-1) 
        Ka =
[𝐃𝐏]
([𝐃]−[𝐃𝐏])([𝐏]−[𝐃𝐏])
                                     (3-2) 
           𝐊𝐚 =
𝟏−𝑭𝟎
𝑭𝟎([𝐏]−[𝐃]+[𝐃]𝑭𝟎)
                                    (3-3) 
In Eq. 3-3, F0 is free fraction for the drug in the original sample, [P] is total 
concentration of soluble protein (HSA or glycated HSA) in sample, and [D] is total 
concentration of the drug.   
Table 3-3 shows values of Ka that were obtained by using Eq. 3-3 and free 
fractions that are listed in Tables 3-1 for each of the examined sulfonylurea drugs with 
gHSA1.  No significant changes in these values were observed at the 95% confidence 
level when protein concentration was varied.  For example, use of 10 µM glimepiride 
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with 15 or 20 µM gHSA1 and 15 µM glimepiride with 20 gHSA1 all gave statistically 
identical global affinity constants in range of 16.8-17.3 ×  105 M−1.  This result 
indicated that changes in the sample concentration did not significantly affect the 
estimated values for these global affinity constants.  In addition, it was found that the 
binding constants shown in Tables 3-3 and 3-4 for glimepiride with samples of gHSA1 
and gHSA2 were significantly different at the 95% confidence level versus the values 
that were determined previously for this drug with normal HSA, as shown previously 
in Table 2-3.  Similar results were obtained for other drugs and with either gHSA1 or 
gHSA2, which indicated that glycation can affect the binding constants for second-
generation sulfonylurea drugs.  
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Table 3-3.  Estimation of overall affinity constants for sulfonylurea drugs with 
gHSA1 by using an HSA affinity microcolumna 
 
Drug and sample Affinity constant, Ka (× 105 M-1) 
Glipizide (10 μM)  
    + gHSA1 (20 μM) 
4.1 (± 2.4) 
Glibenclamide (10 μM)  
    + gHSA1 (10 μM) 
          17.1 (± 6.8) 
Glimepiride (10 μM)  
    + gHSA1 (10 μM) 
          7.2 (± 2.8) 
 
aThe overall affinity constants from this study are based on the free drug fractions listed 
in Table 3-1 and were calculated by using Eq. 3-3.  The values in parentheses represent 
a range of ± 1 S.D. (n = 4).  The level of glycation for gHSA1 was 1.40 (± 0.06) mol 
hexose/mol HSA. 
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Table 3-4.  Estimation of overall affinity constants for sulfonylurea drugs with 
gHSA2 by using an HSA affinity microcolumna 
 
Drug and sample Affinity constant, Ka (× 105 M-1) 
Glipizide (10 μM)  
    + gHSA2 (20 μM) 
2.9 (± 0.8) 
Glibenclamide (10 μM)  
    + gHSA2 (10 μM) 
          14.7 (± 6.2) 
Glimepiride (10 μM)  
    + gHSA2 (10 μM) 
          6.1 (± 2.4) 
aThe overall affinity constants from this study are based on the free drug fractions listed 
in Table 3-2 and were calculated by using Eq. 3-3. The values in parentheses represent 
a range of ±1 S.D. (n = 4).  The level of glycation for gHSA2 was 3.24 (± 0.06) mol 
hexose/mol HSA. 
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5.  Conclusions 
This study used ultrafast affinity extraction to measure free fractions for several 
second-generation sulfonylurea drugs with glycated HSA and to estimate the global 
affinities for these interactions.  In the future, clinical sample from diabetic patients 
could also be examined by this approach. The results shows that glycation of HSA can 
have a significant change on the overall affinity of HSA for these sulfonylurea drugs.  
This changes may be useful in explaining why the effectiveness of such drugs may vary 
in patients with controlled versus advanced diabetes.17,25,29,30,45-49  An advantage to the 
approach that was used in this study is its ability to directly examine drug-protein 
binding in solution.18,24–26,38,48  In addition, a single type of microcolumn (i.e., 
containing normal HSA) could be used to study binding constant by the given drugs 
with different forms of HSA.  This method also required only small sample volumes 
and provided results within only a few minutes per injection.   
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Chapter 4 
Summary and future work 
1. Summary  
Using of HPAC and HSA affinity microcolumns to measure the free fractions 
of sulfonylurea drugs in the presence of HSA. Sulfonylurea drugs that were examined 
were glipizide, glibenclamide and glimepiride. Types of HSA that were used were 
glycated HSA and normal HSA. Studies carried out by using this technique provide fast 
measurements of free fractions and could be easily automated. Binding constant 
obtained from free fractions showed good agreement with literature values, which 
indicated that the technique is a valid method for pharmaceutical research or new drug 
discovery.  Also, data obtained by the technique can be used in clinical analysis or to 
develop improved treatment regimens for use by pharmaceutical chemists or doctors 
who are treating diabetic patients. 
The binding of normal HSA with these sulfonylurea drugs was studied in 
Chapter 2.  The chapter illustrated an approach for measuring apparent free fractions 
by a single-column system.  Factors that were considered in optimizing the system 
included flow rate, column residence time and back pressure. Optimum flow rates 
obtained for single-column system were then used in a two-column system for 
measurement of free drug fractions at therapeutic levels. The free fractions determined 
on both the single-column system and two-column system were also used to estimate 
the binding constant and dissociation rate constant for each drug with normal HSA.  
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The values showed good agreement with literature values or fell within the range of 
literature values that have been reported for the same or similar drugs.  Chapter 3 used 
a single-column approach to examine binding by the same drugs with glycated HSA 
and to see how different degrees of glycation influenced binding by sulfonylurea drugs 
to HSA. For instance, the binding constant of glipizide with normal HSA, as obtained 
with the single-column system was 5.4 × 105 M-1, while the values for glipizide with 
gHSA1 and gHSA2 were 4.0 and 3.3 × 105 M-1. 
 
2.    Future work 
In future work, dissociation rate constants for the sulfonylurea drugs with 
glycated HSA could be determined by using the methods described in Chapter 2.  The 
values can be compared be with those for normal HSA to see how glycation may 
influence dissociation rates of these interactions.  In addition, single- and two-column 
systems that were used in this project can be used to examine the free fractions of the 
sulfonylurea drugs in clinical samples or to see how advanced glycation end products 
(AGEs) may affect binding of drugs to HSA.1–3 Data that can be obtained through such 
research should result in a better understanding of how glycation can change 
interactions of drugs with HSA during diabetes.  This information, in turn, should aid 
in later development of better patient treatment based on sulfonylureas and related 
drugs. 
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